Compare AbbVie Inc (ABBV) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs BlackRock TCP Capital Corp — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while BlackRock TCP Capital Corp trades at $3.19 (market cap $268.49M). The key difference: AbbVie Inc is far larger — about 1675.7× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.25%). Which is the better fit depends on your goals.
| ABBV | TCPC | |
|---|---|---|
Market Cap | $449.91B | $268.49M |
Sector | Health | Financials |
52-Week High | $261.07 | $7.90 |
52-Week Low | $184.85 | $3.14 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 26.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
TCPC trades at $3.25, down 3.27% on the day, with a bearish technical outlook and negative revenue trends. The stock shows a low price-to-book ratio of 0.48 but faces challenges with negative net income and declining profitability. Recent news highlights a shareholder investigation into fiduciary duties, adding to investor concerns amid mixed analyst sentiment.
The outlook remains cautious due to persistent losses and legal scrutiny. Opportunities exist from the discounted book value and dividend yield, but risks from earnings misses and negative cash flow outweigh near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
